yervoy
bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - agenți antineoplazici - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4. yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 și 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.
docetaxel ebewe 10 mg/ml
ebewe pharma ges.m.b.h nfg. kg - austria - docetaxelum - conc. pt. sol. perf. - 10mg/ml - alcaloizi din plante si alte produse naturale taxani
bromhexin labormed 8 mg
labormed pharma sa - romania - bromhexinum - compr. - 8mg - expectorante excl. combinatii cu antitusive mucolitice
mitomicina accord 40 mg
accord healthcare polska sp. z.o.o. - polonia - mitomicinum - pulb. pt. sol. inj./perf. - 40mg - antibiotice citotoxice si substante inrudite alte antibiotice citotoxice
reactin 10 mg
catalent germany schorndorf gmbh - germania - cetirizinum - caps. moi - 10mg - antihistaminice de uz sistemic derivati de piperazine
seroquel xr 150 mg
astrazeneca gmbh - germania - quetiapinum - compr. cu elib. prel. - 150mg - antipsihotice diazepine, oxazepine si tiazepine
seroquel xr 200 mg
astrazeneca gmbh - germania - quetiapinum - compr. cu elib. prel. - 200mg - antipsihotice diazepine, oxazepine si tiazepine
seroquel xr 300 mg
astrazeneca gmbh - germania - quetiapinum - compr. cu elib. prel. - 300mg - antipsihotice diazepine, oxazepine si tiazepine
seroquel xr 400 mg
astrazeneca gmbh - germania - quetiapinum - compr. cu elib. prel. - 400mg - antipsihotice diazepine, oxazepine si tiazepine
seroquel xr 50 mg
astrazeneca gmbh - germania - quetiapinum - compr. cu elib. prel. - 50mg - antipsihotice diazepine, oxazepine si tiazepine